ScienceDaily: Latest Science News
After the manufacturer of the Alzheimer's drug memantine submitted a supplementary analysis of study data, the German Institute for Quality and Efficiency in Health Care sees proof of a benefit of the drug for cognitive function, as well as indications of a benefit for activities of daily living, at least for a treatment period of 6 months. This changes the conclusions of the first benefit assessment of 2009.
Sent with Reeder
No comments:
Post a Comment